Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Thoracic Malignancies
•
Medical Oncology
What is the preferred concurrent chemotherapy regimen for limited stage small cell lung cancer with severe reaction to etoposide?
Related Questions
Should a patient with resected stage IIIA lung adenocarcinoma harboring an STK11 mutation receive adjuvant immune checkpoint inhibitor therapy following the completion of adjuvant chemotherapy?
What is the role of consolidative durvalumab and prophylactic cranial irradiation in patients with stage I small cell lung cancer?
How would you treat a patient with metastatic NSCLC, adenocarcinoma subtype with BRAF V600K mutation, PD-L1 >50% with progression on 1st line chemo-immunotherapy?
When should a biopsy be obtained to rule out small cell transformation in a patient with stage IV NSCLC and an EGFR mutation?
Do you offer adjuvant durvalumab for stage I small cell lung cancer following SBRT or surgery?
Would you change systemic therapy in a patient with SCLC with stable systemic disease but CNS progression?
Will you offer lurbinectedin with atezolizumab for patients with ES-SCLC during maintenance if they had brain metastases at baseline?
Is there a biomarker for which patients benefit from tarlatamab?
Under what circumstances, if any, would you wait on initiating a TKI for metastatic recurrence of a Stage III NSCLC which occurred while on consolidative durvalumab to minimize pneumonitis risk?
When do you recommend incorporating HER2 testing into the diagnostic pathway for tumor types where HER2 overexpression is not commonly assessed?
